How to Build A Sustainable R&D Driven Biotech in China

– A Personal Journey

Speaker: Ting Xu

CEO of AlphaMab and Dingfu Biotarget

3:00 – 4:30 pm, February 19 (Friday), 2016

Smith Building 308 Room

Dana-Farber Cancer Institute

450 Brookline Ave, Boston MA 02115

Drink and snacks will be served

Biography of Dr. Ting Xu

Dr. Ting Xu, founder and CEO of AlphaMab and Dingfu Biotarget in Suzhou, P.R.China. Dr. Xu founded AlphaMab early 2009 and successfully transoform the company an innovative biotherapeutic oriented R&D powerhouse. In 2011, Dingfu Biotarget was set up to focus on development of biologics in tumor immunotherpy.

AlphaMab has so far transferred dozens bisimilars to major pharmaceutical companies in China and other countries. Meanwhile, Alphamab devoted most of its resource into innovative protein/antibody engineering platform and novel biologics. Currently, The company now has in pipeline over 30 mAbs and engineered proteins, mostly innovative, 4 IND filed with CFDA. In operation merely 3 years ago, Dingfu Bio has more than 7 active program ongoing with its first IND planned 2^nd half of 2016.

Prior to AlphaMAb, Dr. Xu had had worked in several USA biotechnology companies developing engineered proteins and also downstream process. Dr. Xu is the recipient of prominent “One thousand talent” rewards and holds adjunct professor positions with Jilin University and Shanghai Institute of Materia Medica. Dr. Xu holds BSc in Biochemistry from Nanjing University,and Ph.D. from Chinese Academy of Science